Neogen Faces Investor Scrutiny After FDA Warning on Fungal-Contaminated HYCOAT

The sudden decline in Neogen's market value occurred outside of the company’s typical earnings cycle, as no financial reports were scheduled until October 6. Market analysts noted that the volatility was driven entirely by the FDA’s findings regarding the safety of the Neogen Vet line. Reports linked the contaminated product to approximately 100 affected horses and at least 20 documented deaths, raising questions about the company’s internal quality control and public disclosures.

Attorneys at SueWallSt are now evaluating whether the company misled shareholders regarding the safety standards of its Animal Safety segment. Investors who purchased NEOG stock at prices potentially inflated by these omissions may be eligible to seek compensation. The firm is currently reviewing brokerage records to determine the extent of the financial impact on shareholders, noting that eligibility for potential recovery extends to those who sold their holdings at a loss following the disclosure of the contamination.